107 related articles for article (PubMed ID: 28422003)
1. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity.
de Souza RC; de Souza FHC; Miossi R; Shinjo SK
Clin Exp Rheumatol; 2017; 35(6):1011-1013. PubMed ID: 28422003
[TBL] [Abstract][Full Text] [Related]
2. Leflunomide as adjuvant treatment of dermatomyositis.
Boswell JS; Costner MI
J Am Acad Dermatol; 2008 Mar; 58(3):403-6. PubMed ID: 18194823
[TBL] [Abstract][Full Text] [Related]
3. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study.
de Souza AW; da Silva MD; Machado LS; Oliveira AC; Pinheiro FA; Sato EI
Scand J Rheumatol; 2012 May; 41(3):227-30. PubMed ID: 22400913
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide use in a cytomegalovirus infection of a patient with dermatomyositis.
Orden AO; Chuluyan JC; Colombini AC; Barbera RF
Rheumatol Int; 2012 Jan; 32(1):273-5. PubMed ID: 21243491
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis.
Sangle VS; Sangle SR; D'Cruz DP
Ann Rheum Dis; 2008 May; 67(5):723. PubMed ID: 18408111
[No Abstract] [Full Text] [Related]
6. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Wang HY; Cui TG; Hou FF; Ni ZH; Chen XM; Lu FM; Xu FF; Yu XQ; Zhang FS; Zhao XZ; Zhao MH; Wang GB; Qian JQ; Cai GY; Zhu TY; Wang YH; Jiang ZP; Li YN; Mei CL; Zou WZ;
Lupus; 2008 Jul; 17(7):638-44. PubMed ID: 18625636
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis.
Galimberti F; Kooistra L; Li Y; Chatterjee S; Fernandez AP
Clin Exp Dermatol; 2018 Dec; 43(8):906-912. PubMed ID: 29856076
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of leflunomide for treatment of refractory inflammatory colorectal polyps in 15 Miniature Dachshunds.
Fukushima K; Eguchi N; Ohno K; Kanemoto H; Takahashi M; Igarashi H; Ohmi A; Nakashima K; Tsujimoto H
J Vet Med Sci; 2016 Feb; 78(2):265-9. PubMed ID: 26460312
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.
Maddison P; Kiely P; Kirkham B; Lawson T; Moots R; Proudfoot D; Reece R; Scott D; Sword R; Taggart A; Thwaites C; Williams E
Rheumatology (Oxford); 2005 Mar; 44(3):280-6. PubMed ID: 15657072
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs.
Sato M; Veir JK; Legare M; Lappin MR
J Vet Intern Med; 2017 Sep; 31(5):1502-1507. PubMed ID: 28833582
[TBL] [Abstract][Full Text] [Related]
11. [Effects of leflunomide combined with hormone therapy for refractory IgA nephropathy].
Rong L; Liu ZR
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):893-4. PubMed ID: 17584664
[TBL] [Abstract][Full Text] [Related]
12. [Leflunomide--a new drug for pharmacological immunomodulation].
Wozel G; Pfeiffer C
Hautarzt; 2002 May; 53(5):309-15. PubMed ID: 12063741
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
[TBL] [Abstract][Full Text] [Related]
15. Clinically amyopathic dermatomyositis: analysis of a monocentric cohort.
Neri R; Barsotti S; Iacopetti V; Tripoli A; dʼAscanio A; Tavoni AG; Mosca M; Bombardieri S
J Clin Neuromuscul Dis; 2014 Jun; 15(4):157-60. PubMed ID: 24872214
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease.
Zhou J; Zhang Y; Liu G; Li J; Xu R; Huang J
Clin Nephrol; 2013 Aug; 80(2):121-9. PubMed ID: 23458173
[TBL] [Abstract][Full Text] [Related]
17. Leflunomide as a novel treatment option in severe atopic dermatitis.
Schmitt J; Wozel G; Pfeiffer C
Br J Dermatol; 2004 Jun; 150(6):1182-5. PubMed ID: 15214907
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of leflunomide combined with prednisone in the treatment of refractory nephrotic syndrome.
Liu Y; Qu X; Chen W; Zhang Y; Liu L
Ren Fail; 2016 Nov; 38(10):1616-1621. PubMed ID: 27819170
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of remission with leflunomide in Wegener's granulomatosis.
Metzler C; Fink C; Lamprecht P; Gross WL; Reinhold-Keller E
Rheumatology (Oxford); 2004 Mar; 43(3):315-20. PubMed ID: 14963200
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids.
Ramanan AV; Campbell-Webster N; Ota S; Parker S; Tran D; Tyrrell PN; Cameron B; Spiegel L; Schneider R; Laxer RM; Silverman ED; Feldman BM
Arthritis Rheum; 2005 Nov; 52(11):3570-8. PubMed ID: 16255046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
